Recruitment of FBXO22 for targeted degradation of NSD2

David Y Nie^#^{1

2

3}, John R Tabor^#⁴, Jianping Li^{5

6}, Maria Kutera^{1

2

3}, Jonathan St-Germain², Ronan P Hanley^{4

7}, Esther Wolf⁸, Ethan Paulakonis⁹, Tristan M G Kenney^{1

2

3}, Shili Duan^{1

2}, Suman Shrestha^{1

2}, Dominic D G Owens^{1

10}, Matthew E R Maitland¹, Ailing Pon¹, Magdalena Szewczyk¹, Anthony Joseph Lamberto⁵, Michael Menes⁵, Fengling Li¹, Linda Z Penn^{2

3}, Dalia Barsyte-Lovejoy^{1

11}, Nicholas G Brown^{9

12}, Anthony M Barsotti¹³, Andrew W Stamford¹³, Jon L Collins¹⁴, Derek J Wilson⁸, Brian Raught^{2

3}, Jonathan D Licht⁵, Lindsey I James^{15

16}, Cheryl H Arrowsmith^{17

18

19}

Affiliations

¹ Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
² Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
³ Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
⁴ Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
⁵ University of Florida Health Cancer Center, Gainesville, FL, USA.
⁶ Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
⁷ C4 Therapeutics, Watertown, MA, USA.
⁸ Department of Chemistry, York University, Toronto, Ontario, Canada.
⁹ Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.
¹⁰ Amphista Therapeutics, Cambridge, UK.
¹¹ Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
¹² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹³ Deerfield Discovery and Development, Deerfield Management, New York, NY, USA.
¹⁴ Office of the Vice Chancellor for Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹⁵ Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu.
¹⁶ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu.
¹⁷ Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.
¹⁸ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.
¹⁹ Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.

^# Contributed equally.

PMID: 38965384
PMCID: PMC11581931 (available on 2025-12-01)
DOI: 10.1038/s41589-024-01660-y

Recruitment of FBXO22 for targeted degradation of NSD2

David Y Nie et al. Nat Chem Biol. 2024 Dec.

. 2024 Dec;20(12):1597-1607.

doi: 10.1038/s41589-024-01660-y. Epub 2024 Jul 4.

Authors

Affiliations

¹ Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
² Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
³ Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
⁴ Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
⁵ University of Florida Health Cancer Center, Gainesville, FL, USA.
⁶ Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
⁷ C4 Therapeutics, Watertown, MA, USA.
⁸ Department of Chemistry, York University, Toronto, Ontario, Canada.
⁹ Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.
¹⁰ Amphista Therapeutics, Cambridge, UK.
¹¹ Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
¹² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹³ Deerfield Discovery and Development, Deerfield Management, New York, NY, USA.
¹⁴ Office of the Vice Chancellor for Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹⁵ Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu.
¹⁶ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu.
¹⁷ Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.
¹⁸ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.
¹⁹ Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.

^# Contributed equally.

PMID: 38965384
PMCID: PMC11581931 (available on 2025-12-01)
DOI: 10.1038/s41589-024-01660-y

Abstract

Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins for proteasomal degradation. Here we describe a TPD strategy involving the recruitment of FBXO22 to induce degradation of the histone methyltransferase and oncogene NSD2. UNC8732 facilitates FBXO22-mediated degradation of NSD2 in acute lymphoblastic leukemia cells harboring the NSD2 gain-of-function mutation p.E1099K, resulting in growth suppression, apoptosis and reversal of drug resistance. The primary amine of UNC8732 is metabolized to an aldehyde species, which engages C326 of FBXO22 to recruit the SCF^FBXO22 Cullin complex. We further demonstrate that a previously reported alkyl amine-containing degrader targeting XIAP is similarly dependent on SCF^FBXO22. Overall, we present a potent NSD2 degrader for the exploration of NSD2 disease phenotypes and a new FBXO22-recruitment strategy for TPD.

PubMed Disclaimer

Conflict of interest statement

Competing interests: D.D.G.O. is an employee of Amphista Therapeutics, a company that is developing TPD therapeutic platforms. A.M.B. and A.W.S. are employees of Deerfield Management Company, a healthcare-focused investment management firm. The remaining authors declare no competing interests.

Update of

Recruitment of FBXO22 for Targeted Degradation of NSD2.
Nie DY, Tabor JR, Li J, Kutera M, St-Germain J, Hanley RP, Wolf E, Paulakonis E, Kenney TMG, Duan S, Shrestha S, Owens DDG, Pon A, Szewczyk M, Lamberto AJ, Menes M, Li F, Barsyte-Lovejoy D, Brown NG, Barsotti AM, Stamford AW, Collins JL, Wilson DJ, Raught B, Licht JD, James LI, Arrowsmith CH. Nie DY, et al. bioRxiv [Preprint]. 2023 Nov 30:2023.11.01.564830. doi: 10.1101/2023.11.01.564830. bioRxiv. 2023. Update in: Nat Chem Biol. 2024 Dec;20(12):1597-1607. doi: 10.1038/s41589-024-01660-y. PMID: 37961297 Free PMC article. Updated. Preprint.

References

1. Békés M, Langley DR & Crews CM PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022). - PMC - PubMed
1. Humphreys LM, Smith P, Chen Z, Fouad S & D’Angiolella V The role of E3 ubiquitin ligases in the development and progression of glioblastoma. Cell Death Differ. 28, 522–537 (2021). - PMC - PubMed
1. Kramer LT & Zhang X Expanding the landscape of E3 ligases for targeted protein degradation. Curr. Res. Chem. Biol. 2, 100020 (2022).
1. Schapira M, Calabrese MF, Bullock AN & Crews CM Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019). - PubMed
1. Sun J et al. Downregulation of miR-21 inhibits the malignant phenotype of pancreatic cancer cells by targeting VHL. Onco Targets Ther. 12, 7215–7226 (2019). - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Recruitment of FBXO22 for targeted degradation of NSD2

Affiliations

Recruitment of FBXO22 for targeted degradation of NSD2

Authors

Affiliations

Abstract

Conflict of interest statement

Update of

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources